Frank Brink - Accelerate Diagnostics Independent Director
| AXDX Stock | USD 0.92 0.02 2.13% |
Director
Mr. Frank J. M. ten Brink is Independent Director of Accelerate Diagnostics, Inc. effective since March 6, 2013. Mr. ten Brink currently serves as Senior Vice President of Mergers and Acquisitions at Stericycle, Inc. where he also served as Executive Vice President, Chief Financial Officer and Chief Administrative Officer from June 1997 to August 2014. He has over 16 years of finance experience in high growth environments, mergers and acquisitions. Prior to joining Stericycle, he was Senior Vice President and Chief Financial Officer with Telular Corporation. Between 1991 and 1995, he was Vice President and Chief Financial Officer of Hexacomb Corporation since 2013.
| Age | 61 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 3950 South Country Club Road, Tucson, AZ, United States, 85714 |
| Phone | 520 365 3100 |
| Web | https://acceleratediagnostics.com |
Accelerate Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.7007) % which means that it has lost $0.7007 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.25 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.87). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2024.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Michael Kauffman | Kezar Life Sciences | 54 | |
| Jason Dinges | Kezar Life Sciences | 42 | |
| Franklin Berger | Kezar Life Sciences | 68 | |
| John Fowler | Kezar Life Sciences | 52 | |
| Graham Cooper | Kezar Life Sciences | 48 | |
Management Performance
| Return On Asset | -0.7 |
Accelerate Diagnostics Leadership Team
Elected by the shareholders, the Accelerate Diagnostics' board of directors comprises two types of representatives: Accelerate Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Accelerate. The board's role is to monitor Accelerate Diagnostics' management team and ensure that shareholders' interests are well served. Accelerate Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Accelerate Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rita Boukamel, Senior EMEA | ||
| Lawrence Mehren, CEO and President and Director | ||
| Thomas Brown, Independent Director | ||
| John Patience, Independent Chairman of the Board | ||
| Ron Price, Senior Vice President Head - Commercial Operations | ||
| Charles Watts, Director | ||
| Steve Reichling, CFO, Chief Accounting Officer and Secretary | ||
| Frank Brink, Independent Director | ||
| David Patience, Principal CFO | ||
| Lawrence Mertz, Chief Officer | ||
| Michael Bridge, Gen VP | ||
| Laura Costa, VP Support | ||
| Jack Phillips, President CEO | ||
| Maya Gowri, Senior Operations | ||
| Mark Miller, Independent Director | ||
| Pete Bantock, Chief Culture Officer and Head of HR | ||
| Cherif Bousselham, VP EMEA | ||
| Chris Thode, Senior Commercial | ||
| John Phillips, Part Time COO | ||
| Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa | ||
| Jack Schuler, Independent Director | ||
| Gretchen Strohminger, Senior Culture | ||
| Tom Brown, Independent Director | ||
| John Meduri, Chief Officer | ||
| Matthew Strobeck, Independent Director | ||
| Laura Pierson, Investor Officer |
Accelerate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Accelerate Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.7 | ||||
| Operating Margin | (3.54) % | ||||
| Current Valuation | 46.41 M | ||||
| Shares Outstanding | 21.66 M | ||||
| Shares Owned By Insiders | 37.11 % | ||||
| Shares Owned By Institutions | 12.82 % | ||||
| Number Of Shares Shorted | 373.71 K | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 1.60 X | ||||
| Revenue | 12.06 M |
Pair Trading with Accelerate Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Accelerate Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Accelerate Stock
| 0.71 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.76 | ME | 23Andme Holding | PairCorr |
Moving against Accelerate Stock
| 0.75 | YS | YS Biopharma | PairCorr |
| 0.61 | DOMH | Dominari Holdings Earnings Call This Week | PairCorr |
| 0.45 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Accelerate Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Accelerate Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Accelerate Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Accelerate Diagnostics to buy it.
The correlation of Accelerate Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Accelerate Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Accelerate Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Accelerate Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.94) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.